2023 Çѱ¹¸Á¸·ÇÐȸ ÇÏ°èÇмú´ëȸ (2ÀÏÂ÷) : 2023-06-17
±³À°ÀÏÀÚ : 2023-06-17
±³À°Àå¼Ò : ÀÎÅͺҰíÈ£ÅÚ ÄÁº¥¼Ç2Ȧ
±³À°ÁÖÁ¦ : 2023 Çѱ¹¸Á¸·ÇÐȸ ÇÏ°èÇмú´ëȸ (2ÀÏÂ÷)
ÁÖÃÖ±â°ü : ´ëÇѾȰúÇÐȸ
½ÃÇà±â°ü(ÁöºÎ/°ú) : Çѱ¹¸Á¸·ÇÐȸ
´ã´çÀÚ : ¹ÚÀ±Á¤
¿¬¶ôó : 02-471-6520
À̸ÞÀÏ : retina@retina.or.kr
±³À°Á¾·ù : ¾È°ú
Âü¼®¿¹»óÀÎ : 150¸í
Èñ¸ÁÆòÁ¡ : 2Á¡
Áö¿ª : ´ë±¸±¤¿ª½Ã
±³À°½Ã°£ : 2 ½Ã°£ 32ºÐ
¼¼ºÎ¼ö°·á : 50,000¿ø
ºñ°í
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 06¿ù 17ÀÏ ÀÎÅͺҰíÈ£ÅÚ ÄÁº¥¼Ç2Ȧ 08:00~08:07 [ÃʷϹßÇ¥] À¯Àü¼º ¸Á¸·ÁúȯÀÇ Áø´ÜÀ» À§ÇÑ Next-Generation Sequencing ù°æÇè ³²±âÅÂ(Á¦ÁÖ´ë)
±³À°½Ã°£ 06¿ù 17ÀÏ ÀÎÅͺҰíÈ£ÅÚ ÄÁº¥¼Ç2Ȧ 08:07~08:14 [ÃʷϹßÇ¥] Clinical diagnosis and characteristics in Korean patients with RPE65-associated retinal dystrophy ±è»óÁø(¼º±Õ°ü´ë)
±³À°½Ã°£ 06¿ù 17ÀÏ ÀÎÅͺҰíÈ£ÅÚ ÄÁº¥¼Ç2Ȧ 08:14~08:21 [ÃʷϹßÇ¥] Detection of Alu insertion in RP1 gene in patients with retinitis pigmentosa using whole genome sequencing ÀÌÁÖ¿ë(¼¿ï¾Æ»êº´¿ø)
±³À°½Ã°£ 06¿ù 17ÀÏ ÀÎÅͺҰíÈ£ÅÚ ÄÁº¥¼Ç2Ȧ 08:21~08:28 [ÃʷϹßÇ¥] Whole Genome Sequencing for Inherited Retinal Diseases in Korea¡¯s National Project of Bio Big Data ÁÖ±¤½Ä(¼¿ï´ë)
±³À°½Ã°£ 06¿ù 17ÀÏ ÀÎÅͺҰíÈ£ÅÚ ÄÁº¥¼Ç2Ȧ 08:28~08:35 [ÃʷϹßÇ¥] Genetic Characteristics of Korean Inherited Retinal Disease patients: a Multicenter Study by Korean Eye Gene Consortium ¹è¼®Çö(Çѱæ¾È°úº´¿ø)
±³À°½Ã°£ 06¿ù 17ÀÏ ÀÎÅͺҰíÈ£ÅÚ ÄÁº¥¼Ç2Ȧ 08:35~08:42 [ÃʷϹßÇ¥] OCT biomarkers in choroideremia and choroideremia carriers ÀÌÀº°æ(¼¿ï´ë)
ÈÞ½Ä 06¿ù 17ÀÏ 08:42~08:55 Break time ()
±³À°½Ã°£ 06¿ù 17ÀÏ ÀÎÅͺҰíÈ£ÅÚ ÄÁº¥¼Ç2Ȧ 08:55~09:04 [ÃʷϹßÇ¥] Influence of Internal limiting membrane peeling during idiopathic epiretinal membrane removal: A prospective study ¹Ú¿îö(¼¿ï´ë)
±³À°½Ã°£ 06¿ù 17ÀÏ ÀÎÅͺҰíÈ£ÅÚ ÄÁº¥¼Ç2Ȧ 09:04~09:13 [ÃʷϹßÇ¥] What is the ideal surgery for RRD in young patients?: T-shape small incision SB ±èÈ«±Ô(´Ü±¹´ë)
±³À°½Ã°£ 06¿ù 17ÀÏ ÀÎÅͺҰíÈ£ÅÚ ÄÁº¥¼Ç2Ȧ 09:13~09:22 [ÃʷϹßÇ¥] Factors triggering epiretinal membrane development and progression before and after par plana vitrectomy for rhegmatogenous retinal detachment ¾ÈÁöÀ±(¼¿ï´ë)
±³À°½Ã°£ 06¿ù 17ÀÏ ÀÎÅͺҰíÈ£ÅÚ ÄÁº¥¼Ç2Ȧ 09:22~09:31 [ÃʷϹßÇ¥] º¯ÇüµÈ LÀÚ ÇüÅÂÀÇ È²¹Ýµ¹¸¢¼ú : pearls and tips ±èÁß°ï(¼¿ï¾Æ»êº´¿ø)
±³À°½Ã°£ 06¿ù 17ÀÏ ÀÎÅͺҰíÈ£ÅÚ ÄÁº¥¼Ç2Ȧ 09:31~09:40 [ÃʷϹßÇ¥] Àΰø¼öÁ¤Ã¼Å»±¸ ȯÀÚ¿¡¼ ½ÃÇàÇÏ´Â ³ªÀÇ ¹«ºÀÇÕÀΰø¼öÁ¤Ã¼°ø¸·°íÁ¤¼ú(¾ß¸¶³×¼ú±â) Áõ·Ê ¸®ºä ÀÌÁ¤È£(Àߺ¸´Â¾È°ú)
±³À°½Ã°£ 06¿ù 17ÀÏ ÀÎÅͺҰíÈ£ÅÚ ÄÁº¥¼Ç2Ȧ 09:40~09:49 [ÃʷϹßÇ¥] º´ÇÕ¼ö¼úÁß ÃÊÀ½ÆÄ À¯È¼ú°ú Àΰø¼öÁ¤Ã¼»ðÀÔ¼ú±â¿¡ ´ëÇÑ ¼±ÅûçÇ× ±èÁ¾¿í(¿ì¸®¾È°ú)
ÈÞ½Ä 06¿ù 17ÀÏ 09:49~10:00 Break time ()
±³À°½Ã°£ 06¿ù 17ÀÏ ÀÎÅͺҰíÈ£ÅÚ ÄÁº¥¼Ç2Ȧ 10:00~10:07 [ÃʷϹßÇ¥] Changes of Retinal Nonperfusion in Diabetic Macular Edema Following Anti-VEGF Loading Injections ±è±â¿µ(°æÈñ´ë)
±³À°½Ã°£ 06¿ù 17ÀÏ ÀÎÅͺҰíÈ£ÅÚ ÄÁº¥¼Ç2Ȧ 10:07~10:14 [ÃʷϹßÇ¥] RAP: The Progressive Disease ±èÀçÈÖ(±è¾È°úº´¿ø)
±³À°½Ã°£ 06¿ù 17ÀÏ ÀÎÅͺҰíÈ£ÅÚ ÄÁº¥¼Ç2Ȧ 10:14~10:21 [ÃʷϹßÇ¥] Long-term efficacy and safety of intravitreal brolucizumab injections for neovascular age-related macular degeneration: a multicenter retrospective real-world study ¿ì¼¼ÁØ(¼¿ï´ë)
±³À°½Ã°£ 06¿ù 17ÀÏ ÀÎÅͺҰíÈ£ÅÚ ÄÁº¥¼Ç2Ȧ 10:21~10:28 [ÃʷϹßÇ¥] Phase III Randomized Clinical Trial Comparing SB15 with Reference Aflibercept in Neovascular Age-Related Macular Degeneration: 56-Week Results »ç°ø¹Î(¿µ³²´ë)
±³À°½Ã°£ 06¿ù 17ÀÏ ÀÎÅͺҰíÈ£ÅÚ ÄÁº¥¼Ç2Ȧ 10:28~10:35 [ÃʷϹßÇ¥] Delayed anti-vascular endothelial growth factor (VEGF) treatment in the patients with neovascular age-related macular degeneration during the coronavirus disease pandemic: 2-year follow-up °°æÅÂ(°è¸í´ë)
±³À°½Ã°£ 06¿ù 17ÀÏ ÀÎÅͺҰíÈ£ÅÚ ÄÁº¥¼Ç2Ȧ 10:35~10:42 [ÃʷϹßÇ¥] Early outer nuclear layer recovery during the aflibercept loading correlates to 1-year visual outcome in type 1 choroidal neovascularization of neovascular age-related macular degeneration ¼ÀÇÁ¾(ÃæºÏ´ë)
±³À°½Ã°£ 06¿ù 17ÀÏ ÀÎÅͺҰíÈ£ÅÚ ÄÁº¥¼Ç2Ȧ 10:42~10:49 [ÃʷϹßÇ¥] Quantitative analysis of change in choriocapillary flow after photodynamic therapy in central serous chorioretinopathy ±è·¡¿µ(°¡Å縯´ë)
±³À°½Ã°£ 06¿ù 17ÀÏ ÀÎÅͺҰíÈ£ÅÚ ÄÁº¥¼Ç2Ȧ 10:49~10:56 [ÃʷϹßÇ¥] Macular Microvasculature in Diabetic Retinopathy with Systemic Hypertension À̹οì(°Ç¾ç´ë)